New Delhi, May 23 (UNI) Strides Arcolab today said it has received the ANDA approval from the US Food and Drug Administration for Rifampicin Injection USP in 600 mg/vial.
'It has received the approval for Rifampicin. The product is licenced to Akron-Strides, a JV between strides and Akron,'' a company statement said.
Strides manufactures pharmaceutical formulations in various doses forms, including capsules, tablets, liquid injectables and has a major presence in developing countries like Africa, Latin America, Asia, Canada, and part of Europe.
UNI SR AK GC1922